{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:24:19Z","timestamp":1776896659987,"version":"3.51.2"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Innovation Fund","award":["01VSF16034"],"award-info":[{"award-number":["01VSF16034"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Unwanted anticholinergic effects are both underestimated and frequently overlooked. Failure to identify adverse drug reactions (ADRs) can lead to prescribing cascades and the unnecessary use of over-the-counter products. The objective of this systematic review and meta-analysis is to explore and quantify the frequency and severity of ADRs associated with amitriptyline vs. placebo in randomized controlled trials (RCTs) involving adults with any indication, as well as healthy individuals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic search in six electronic databases, forward\/backward searches, manual searches, and searches for Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval studies, will be performed. Placebo-controlled RCTs evaluating amitriptyline in any dosage, regardless of indication and without restrictions on the time and language of publication, will be included, as will healthy individuals. Studies of topical amitriptyline, combination therapies, or including &lt;\u2009100 participants, will be excluded. Two investigators will screen the studies independently, assess methodological quality, and extract data on design, population, intervention, and outcomes ((non-)anticholinergic ADRs, e.g., symptoms, test results, and adverse drug events (ADEs) such as falls). The primary outcome will be the frequency of anticholinergic ADRs as a binary outcome (absolute number of patients with\/without anticholinergic ADRs) in amitriptyline vs. placebo groups. Anticholinergic ADRs will be defined by an experienced clinical pharmacologist, based on literature and data from <jats:italic>Martindale: The Complete Drug Reference<\/jats:italic>. Secondary outcomes will be frequency and severity of (non-)anticholinergic ADRs and ADEs. The information will be synthesized in meta-analyses and narratives. We intend to assess heterogeneity using meta-regression (for indication, outcome, and time points) and <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> statistics. Binary outcomes will be expressed as odds ratios, and continuous outcomes as standardized mean differences. Effect measures will be provided using 95% confidence intervals. We plan sensitivity analyses to assess methodological quality, outcome reporting etc., and subgroup analyses on age, dosage, and duration of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>We will quantify the frequency of anticholinergic and other ADRs\/ADEs in adults taking amitriptyline for any indication by comparing rates for amitriptyline vs. placebo, hence, preventing bias from disease symptoms and nocebo effects. As no standardized instrument exists to measure it, our overall estimate of anticholinergic ADRs may have limitations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Systematic review registration<\/jats:title>\n                <jats:p>Submitted to PROSPERO; assignment is in progress.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13643-020-01296-8","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T23:02:32Z","timestamp":1584486152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Adverse drug reactions associated with amitriptyline\u00a0\u2014\u00a0protocol for a systematic multiple-indication review and meta-analysis"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5242-1857","authenticated-orcid":false,"given":"Maria-Sophie","family":"Brueckle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth T.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svenja E.","family":"Seide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Pilz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Isabel","family":"Gonzalez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Truc Sophia","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Harder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul P.","family":"Glasziou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinand M.","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Muth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"key":"1296_CR1","unstructured":"World Health Organization. Integrating care for people with multimorbidity: what does the evidence tell us? 2017 [Available from: http:\/\/www.euro.who.int\/en\/about-us\/partners\/observatory\/news\/news\/2017\/04\/integrating-care-for-people-with-multimorbidity-what-does-the-evidence-tell-us]. Last access: 19th August 2019."},{"issue":"7","key":"1296_CR2","doi-asserted-by":"publisher","first-page":"e011613","DOI":"10.1136\/bmjopen-2016-011613","volume":"6","author":"Christiane Muth","year":"2016","unstructured":"Muth C, Harder S, Uhlmann L, G\u00fcthlin C, Fullerton B, Erler A, et al. Pilot study to test the feasibility of a trial design and complex intervention on PRIoritising MUltimedication in Multimorbidity in general practices (PRIMUMpilot). BMJ Open. 2016;6:e011613.","journal-title":"BMJ Open"},{"key":"1296_CR3","doi-asserted-by":"publisher","first-page":"h1059","DOI":"10.1136\/bmj.h1059","volume":"350","author":"A Marengoni","year":"2015","unstructured":"Marengoni A, Onder G. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ. 2015;350:h1059.","journal-title":"BMJ"},{"key":"1296_CR4","unstructured":"World Health Organization. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting 1969 [Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4257024\/]. Last access: 1st July 2019."},{"issue":"3","key":"1296_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40264-013-0019-9","volume":"36","author":"JK Aronson","year":"2013","unstructured":"Aronson JK. Distinguishing hazards and harms, adverse drug effects and adverse drug reactions : implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring. Drug Saf. 2013;36(3):147\u201353.","journal-title":"Drug Saf"},{"issue":"10","key":"1296_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2165\/00002018-200528100-00003","volume":"28","author":"JK Aronson","year":"2005","unstructured":"Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28(10):851\u201370.","journal-title":"Drug Saf"},{"key":"1296_CR7","first-page":"412","volume-title":"Arzneiverordnungsreport 2017","author":"B Lemmer","year":"2017","unstructured":"Lemmer B. Bronchospasmolytika und Antiasthmatika. In: DP US, Ludwig W-D, Klauber J, editors. Arzneiverordnungsreport 2017. Germany: Springr-Verlag GmbH; 2017. p. 412\u20133."},{"issue":"7","key":"1296_CR8","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","volume":"56","author":"ML Chew","year":"2008","unstructured":"Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc. 2008;56(7):1333\u201341.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"1296_CR9","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1176\/ajp.149.10.1393","volume":"149","author":"L Tune","year":"1992","unstructured":"Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry. 1992;149(10):1393\u20134.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1296_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/bcpt.12140","volume":"114","author":"H Kersten","year":"2014","unstructured":"Kersten H, Wyller TB. Anticholinergic drug burden in older people\u2019s brain - how well is it measured? Basic Clin Pharmacol Toxicol. 2014;114(2):151\u20139.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1296_CR11","doi-asserted-by":"crossref","unstructured":"Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev. 2012(2):CD009138.","DOI":"10.1002\/14651858.CD009138.pub2"},{"key":"1296_CR12","unstructured":"European Medicines Agency (EMA). Assessment report : Saroten and associated names 2017 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/saroten-article-30-referral-assessment-report_en.pdf]. Last access: 20th January 2020."},{"key":"1296_CR13","volume-title":"Psychopharmaka","author":"MJM-OB Lohse","year":"2009","unstructured":"Lohse MJM-OB. Psychopharmaka. Heidelberg: Springer; 2009."},{"key":"1296_CR14","doi-asserted-by":"crossref","unstructured":"Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for fibromyalgia in adults (review). Cochrane Database Syst Rev. 2015;(7):CD011824.","DOI":"10.1002\/14651858.CD011824"},{"key":"1296_CR15","doi-asserted-by":"crossref","unstructured":"Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults (review). Cochrane Database Syst Rev. 2015;(7):CD008242.","DOI":"10.1002\/14651858.CD008242.pub3"},{"issue":"5","key":"1296_CR16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.juro.2009.12.106","volume":"183","author":"HE Foster Jr","year":"2010","unstructured":"Foster HE Jr, Hanno PM, Nickel JC, Payne CK, Mayer RD, Burks DA, et al. Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis\/painful bladder syndrome. J Urol. 2010;183(5):1853\u20138.","journal-title":"J Urol"},{"key":"1296_CR17","unstructured":"Gelbe Liste. [Available from: https:\/\/www.gelbe-liste.de\/wirkstoffe\/Amitriptylin-hydrochlorid-75-mg-Tabletten-Zum-Einnehmen_cbf1717e-b734-4aff-9b9b-6f4abcda5024?scope=produkt_24921#ade.]. Last access: 15.01.2019."},{"key":"1296_CR18","unstructured":"MedlinePlus. [Available from: https:\/\/medlineplus.gov\/druginfo\/meds\/a682388.html#other-uses]. Last access: 28th January 2019."},{"key":"1296_CR19","doi-asserted-by":"crossref","unstructured":"Guaiana G, Barbui C, Hotopf M. Amitriptyline versus other types of pharmacotherapy for depression (review). Cochrane Database Syst Rev. 2007(2):CD004186.","DOI":"10.1002\/14651858.CD004186.pub2"},{"key":"1296_CR20","unstructured":"Strobach D. Anticholinerge Arzneistoffe Erkennen, erkl\u00e4ren, ersetzen. Pharmazeutische Zeitung. 2013;41. [Availible from: https:\/\/www.pharmazeutische-zeitung.de\/ausgabe-412013\/erkennen-erklaeren-ersetzen\/]. Accessed 19 Feb 2020."},{"issue":"4","key":"1296_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/00002512-199303040-00004","volume":"3","author":"M Feinberg","year":"1993","unstructured":"Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. 1993;3(4):335\u201348.","journal-title":"Drugs Aging"},{"key":"1296_CR22","doi-asserted-by":"crossref","unstructured":"Magin PJ, Morgan S, Tapley A, McCowan C, Parkinson L, Henderson KM, et al. Anticholinergic medicines in an older primary care population: a cross-sectional analysis of medicines\u2019 levels of anticholinergic activity and clinical indications. J Clin Pharm Ther. 2016.","DOI":"10.1111\/jcpt.12413"},{"issue":"Suppl 21","key":"1296_CR23","first-page":"11","volume":"62","author":"LE Tune","year":"2001","unstructured":"Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(Suppl 21):11\u20134.","journal-title":"J Clin Psychiatry"},{"issue":"315","key":"1296_CR24","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/bmj.315.7115.1096","volume":"25","author":"PA Rochon","year":"1997","unstructured":"Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;25(315):1096\u20139.","journal-title":"BMJ"},{"issue":"389","key":"1296_CR25","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/S0140-6736(17)31188-1","volume":"6","author":"PA Rochon","year":"2017","unstructured":"Rochon PA, Gurwitz JH. The prescribing cascade revisited. Lancet. 2017;6(389):1778\u201380.","journal-title":"Lancet"},{"issue":"9","key":"1296_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1177\/014107680009300903","volume":"93","author":"J Mintzer","year":"2000","unstructured":"Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000;93(9):457\u201362.","journal-title":"J R Soc Med"},{"issue":"14","key":"1296_CR27","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1001\/archinte.1997.00440350031003","volume":"157","author":"MH Beers","year":"1997","unstructured":"Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997;157(14):1531\u20136.","journal-title":"Arch Intern Med"},{"issue":"31\u201332","key":"1296_CR28","first-page":"543","volume":"107","author":"S Holt","year":"2010","unstructured":"Holt S, Schmiedl S, Th\u00fcrmann PA. Potenziell inad\u00e4quate Medikation f\u00fcr \u00e4ltere Menschen: Die PRISCUS-Liste. Deutsches \u00c4rzteblatt. 2010;107(31\u201332):543\u201351 Anhang 10\u201319.","journal-title":"Deutsches \u00c4rzteblatt"},{"issue":"1","key":"1296_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40520-015-0359-7","volume":"28","author":"A Collamati","year":"2016","unstructured":"Collamati A, Martone AM, Poscia A, Brandi V, Celi M, Marzetti E, et al. Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. Aging Clin Exp Res. 2016;28(1):25\u201335.","journal-title":"Aging Clin Exp Res"},{"issue":"10","key":"1296_CR30","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006\u201312.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1296_CR31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/ije\/31.1.140","volume":"31","author":"Diana R Elbourne","year":"2002","unstructured":"Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthingtond HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int Epidemiol Assoc. 2002;31:140\u20139.","journal-title":"International Journal of Epidemiology"},{"key":"1296_CR32","unstructured":"Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. [Available from: www.handbook.cochrane.org]. Accessed 28 Jan 2020."},{"key":"1296_CR33","unstructured":"Martindale: the complete drug reference. Amitriptyline. Royal Pharmaceutical Society 2019 [Available from: https:\/\/about.medicinescomplete.com\/publication\/martindale-the-complete-drug-reference\/]. Last access: 4th February 2019."},{"issue":"2","key":"1296_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1161\/CIRCOUTCOMES.114.001381","volume":"8","author":"B Abell","year":"2015","unstructured":"Abell B, Glasziou P, Hoffmann T. Reporting and replicating trials of exercise-based cardiac rehabilitation: do we know what the researchers actually did? Circ Cardiovasc Qual Outcomes. 2015;8(2):187\u201394.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"1296_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1600-0773.1985.tb01256.x","volume":"56","author":"L Aaltonen","year":"1985","unstructured":"Aaltonen L, Syvalahti E, Iisalo E, Peltomaki T. Anticholinergic activity in the serum of patients receiving maintenance amitriptyline or doxepin therapy. Acta Pharmacol Toxicol (Copenh). 1985;56(1):75\u201380.","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"issue":"4","key":"1296_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s002130000664","volume":"154","author":"J Penttila","year":"2001","unstructured":"Penttila J, Syvalahti E, Hinkka S, Kuusela T, Scheinin H. The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers. Psychopharmacology. 2001;154(4):343\u20139.","journal-title":"Psychopharmacology"},{"issue":"2","key":"1296_CR37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/1440-1681.12857","volume":"45","author":"H Li","year":"2018","unstructured":"Li H, Shin SE, Seo MS, An JR, Ha KS, Han ET, et al. Inhibitory effect of the tricyclic antidepressant amitriptyline on voltage-dependent K(+) channels in rabbit coronary arterial smooth muscle cells. Clin Exp Pharmacol Physiol. 2018;45(2):205\u201312.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"2","key":"1296_CR38","first-page":"299","volume":"220","author":"HJ Leighton","year":"1982","unstructured":"Leighton HJ. Quantitative assessment of the pre- and postsynaptic alpha adrenoceptor antagonist potency of amitriptyline. J Pharmacol Exp Ther. 1982;220(2):299\u2013304.","journal-title":"J Pharmacol Exp Ther"},{"issue":"46","key":"1296_CR39","doi-asserted-by":"publisher","first-page":"9934","DOI":"10.1523\/JNEUROSCI.1004-18.2018","volume":"38","author":"M Kremer","year":"2018","unstructured":"Kremer M, Yalcin I, Goumon Y, Wurtz X, Nexon L, Daniel D, et al. A dual noradrenergic mechanism for the relief of neuropathic allodynia by the antidepressant drugs duloxetine and amitriptyline. J Neurosci. 2018;38(46):9934\u201354.","journal-title":"J Neurosci"},{"issue":"10","key":"1296_CR40","first-page":"669","volume":"54","author":"E Richelson","year":"1979","unstructured":"Richelson E. Tricyclic antidepressants and histamine H1 receptors. Mayo Clin Proc. 1979;54(10):669\u201374.","journal-title":"Mayo Clin Proc"},{"key":"1296_CR41","volume-title":"Sodium channel blocker toxicity [text]: StatPearls publishing","author":"K Dokken","year":"2018","unstructured":"Dokken K, Fairley P. Sodium channel blocker toxicity [text]: StatPearls publishing; 2018. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/."},{"issue":"3","key":"1296_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2165\/00139709-200524030-00013","volume":"24","author":"HK Thanacoody","year":"2005","unstructured":"Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning : cardiovascular toxicity. Toxicol Rev. 2005;24(3):205\u201314.","journal-title":"Toxicol Rev"},{"issue":"3","key":"1296_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/0002-8703(82)90281-2","volume":"103","author":"JB Marshall","year":"1982","unstructured":"Marshall JB, Forker AD. Cardiovascular effects of tricyclic antidepressant drugs: therapeutic usage, overdose, and management of complications. Am Heart J. 1982;103(3):401\u201314.","journal-title":"Am Heart J"},{"issue":"3","key":"1296_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"7109","key":"1296_CR45","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"8","key":"1296_CR46","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/(SICI)1521-4036(199912)41:8<901::AID-BIMJ901>3.0.CO;2-W","volume":"41","author":"J Hartung","year":"1999","unstructured":"Hartung J. An alternative method for meta-analysis. Biom J. 1999;41(8):901\u201316.","journal-title":"Biom J"},{"issue":"12","key":"1296_CR47","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/sim.791","volume":"20","author":"J Hartung","year":"2001","unstructured":"Hartung J, Knapp G. On tests of the overall treatment effect in meta-analysis with normally distributed responses. Stat Med. 2001;20(12):1771\u201382.","journal-title":"Stat Med"},{"issue":"24","key":"1296_CR48","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/sim.1009","volume":"20","author":"Joachim Hartung","year":"2001","unstructured":"Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med. 2001;20(24):3875\u201389.","journal-title":"Statistics in Medicine"},{"issue":"21","key":"1296_CR49","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1002\/sim.1262","volume":"21","author":"JN Jonkman","year":"2002","unstructured":"Jonkman JN. A simple confidence interval for meta-analysis. Stat Med. 2002;21(21):3153\u20139.","journal-title":"Stat Med"},{"issue":"4","key":"1296_CR50","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1081\/SAC-120023885","volume":"32","author":"K Sidik","year":"2003","unstructured":"Sidik K, Jonkman JN. On constructing confidence intervals for a standardized mean difference in meta-analysis. Commun Stat Simul Comput. 2003;32(4):1191\u2013203.","journal-title":"Commun Stat Simul Comput"},{"issue":"3","key":"1296_CR51","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74(3):785\u201394.","journal-title":"Biometrics"},{"key":"1296_CR52","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2019 [Available from: https:\/\/wwwR-projectorg\/] Last access: 28th January 2020."},{"issue":"28","key":"1296_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15280","volume":"15","author":"CA Coupland","year":"2011","unstructured":"Coupland CA, Dhiman P, Barton G, Morriss R, Arthur A, Sach T, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess. 2011;15(28):1\u2013202 iii-iv.","journal-title":"Health Technol Assess"},{"issue":"2","key":"1296_CR54","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/bcp.12617","volume":"80","author":"K Ruxton","year":"2015","unstructured":"Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(2):209\u201320.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1296_CR55","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jpainsymman.2012.12.005","volume":"46","author":"C Sanderson","year":"2013","unstructured":"Sanderson C, Hardy J, Spruyt O, Currow DC. Placebo and nocebo effects in randomized controlled trials: the implications for research and practice. J Pain Symptom Manag. 2013;46(5):722\u201330.","journal-title":"J Pain Symptom Manag"},{"issue":"12","key":"1296_CR56","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jclinepi.2014.08.007","volume":"67","author":"Y-F Chen","year":"2014","unstructured":"Chen Y-F, Hemming K, Chilton PJ, Gupta KK, Altman DG, Lilford RJ. Scientific hypotheses can be tested by comparing the effects of one treatment over many diseases in a systematic review. J Clin Epidemiol. 2014;67(12):1309\u201319.","journal-title":"J Clin Epidemiol"},{"issue":"9422","key":"1296_CR57","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(04)16261-2","volume":"363","author":"JP Vandenbroucke","year":"2004","unstructured":"Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet. 2004;363(9422):1728\u201331.","journal-title":"Lancet"},{"key":"1296_CR58","doi-asserted-by":"crossref","unstructured":"Hansen MP, Thorning S, Aronson JK, Beller EM, Glasziou PP, Hoffmann TC, Del Mar CB. Adverse events in patients taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev. 2015.","DOI":"10.1002\/14651858.CD011825"},{"key":"1296_CR59","first-page":"Cd011825","volume":"1","author":"MP Hansen","year":"2019","unstructured":"Hansen MP, Scott AM, McCullough A, Thorning S, Aronson JK, Beller EM, et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev. 2019;1:Cd011825.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1296_CR60","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1503\/cmaj.140848","volume":"187","author":"M Gillies","year":"2015","unstructured":"Gillies M, Ranakusuma A, Hoffmann T, Thorning S, McGuire T, Glasziou P, et al. Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication. CMAJ. 2015;187(1):E21\u201331.","journal-title":"CMAJ"},{"key":"1296_CR61","doi-asserted-by":"crossref","unstructured":"Guaiana G, Barbui C, Hotopf M. Amitriptyline for depression. Cochrane Database Syst Rev. 2007;(3):CD004186.","DOI":"10.1002\/14651858.CD004186.pub2"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-020-01296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13643-020-01296-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-020-01296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:35:24Z","timestamp":1615941324000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-020-01296-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1296"],"URL":"https:\/\/doi.org\/10.1186\/s13643-020-01296-8","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]},"assertion":[{"value":"7 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}